Business Context and Reporting Period
Company: Landec Corporation (filing as Landec Corporation, formerly associated with Lifecore Biomedical, Inc. via acquisition).
Filing Type: Form 10-K Annual Report.
Period Ended: May 29, 2011.
Overview: Landec designs, develops, and sells polymer products for food, agriculture, and medical devices. Following the acquisition of Lifecore Biomedical, Inc. in April 2010, the Company operates four core segments: Food Products Technology (Apio), Food Export (Cal-Ex), Hyaluronan-based Biomaterials (Lifecore), and Technology Licensing.
Key Financial Metrics
| Metric | Fiscal Year 2011 | Fiscal Year 2010 |
|---|---|---|
| Total Revenues | $276.7 million | $238.2 million |
| Gross Profit | $46.7 million | $33.8 million |
| Gross Margin | 16.9% | 14.2% |
| Operating Income | $8.0 million | $8.0 million |
| Net Income (Applicable to Common Stockholders) | $3.9 million | $4.0 million |
| Diluted EPS | $0.15 | $0.15 |
| Cash and Cash Equivalents | $8.1 million | $27.8 million |
| Total Debt | $19.8 million | $23.8 million |
| Operating Cash Flow | $14.5 million | $7.5 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 16% to $276.7 million, driven primarily by the full-year inclusion of the Lifecore acquisition (Hyaluronan segment) which contributed $32.5 million in revenue compared to $1.5 million in the prior year.
- Segment Performance:
- Food Products Technology: Revenues remained flat at $175.7 million. Gross profit declined 16% due to a $5.0 million negative impact from weather-related produce shortages in California.
- Food Export: Revenues increased 12% to $61.7 million due to higher export volumes, though gross margin compressed to 6.3% from 7.1% due to product mix changes.
- Technology Licensing: Revenues were flat at $6.9 million. The segment recorded a $4.8 million goodwill impairment charge due to uncertainty regarding the Monsanto license agreement.
- Operating Expenses: Total operating expenses increased 50% to $38.7 million. This includes a 113% increase in R&D expenses (driven by Lifecore integration and new product development) and a 39% increase in SG&A expenses.
- Goodwill Impairment: The Company wrote off $4.8 million of goodwill associated with the Technology Licensing reporting unit.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management believes cash from operations and existing cash reserves are sufficient to finance requirements for the next 12 months. The Company anticipates continued significant R&D expenditures to maintain competitive positioning.
- Unusual Items:
- Weather Impact: Cold and wet weather in California reduced gross profit by approximately $5.0 million in the Food Products Technology segment.
- Goodwill Write-off: A $4.8 million non-cash charge was recorded for the Technology Licensing segment due to the uncertainty of the Monsanto purchase option and projected unprofitability of Landec Ag absent the relationship.
- Risks:
- Customer Concentration: Top five customers accounted for 44% of revenues; Costco Wholesale Corp. alone accounted for 16%.
- Supply Chain: Dependence on single-source suppliers for raw materials and vulnerability to weather conditions affecting produce supply.
- Regulatory: Significant reliance on FDA approvals for medical device products (Lifecore) and potential regulatory changes for food packaging.
- Debt Covenants: The Company is subject to restrictive covenants on its $20 million credit facility related to the Lifecore acquisition, including minimum net income and quick ratio requirements.
Investor Verification Checklist
- Weather Sensitivity: Verify the extent of ongoing weather impacts on the Apio produce sourcing and potential future margin compression.
- Monsanto Agreement: Monitor the status of the Monsanto license agreement and the December 2011 decision point regarding the purchase option or termination fee.
- Debt Compliance: Confirm continued compliance with the Wells Fargo credit facility covenants, specifically the minimum net income requirements for the Lifecore subsidiary.
- Customer Concentration: Assess the risk associated with the top customer (Costco) representing 16% of total revenue.
- Lifecore Integration: Evaluate the performance of the Hyaluronan segment against the earn-out targets (up to $10 million contingent consideration) for calendar years 2011 and 2012.